• New Compound Added to Short List of Molecules Targeting Aging Process

    Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.

    Dec 12, 2023

  • For Rare Disease, What’s Missed by Genome Sequencing Still Matters

    Bio-IT World | For almost two decades, members of the life science community bemoaned something that most outsiders never realized: that the “finished” human genome assembly had never actually been finished. Now, thanks to remarkable efforts from the Telomere-to-Telomere (T2T) consortium, we finally have a complete human reference genome.

    Dec 8, 2023

  • The Last Mile In Preventing A Deadly Hospital Infection

    Bio-IT World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

    Dec 6, 2023

  • Bringing Your Research to the Market With Tom Miller

    Bio-IT World | When Tom Miller was a professor at the California Institute of Technology, he built a research program centered around developing AI and data-driven algorithms to help solve chemistry and biological challenges with various research focuses. These scientific innovations led to increasingly translational capabilities, and Miller realized he had to bring his research to a bigger platform.

    Dec 5, 2023

  • Copyright Clearance Center Wins 2023 European Best of Show Award for Scientific Article Exploration Tool

    Bio-IT World | The Bio-IT World community has chosen the 2023 Best of Show Awards Europe winner. The more than 300 event attendees in London were invited to vote for their favorite solutions, and they chose to honor RightFind XML from Copyright Clearance Center (CCC) as the 2023 honoree.

    Nov 30, 2023

  • Follow the Money: AI-Designed De Novo Therapeutics, Spatial Technology, DNA Platform for Rheumatoid Arthritis, More

    Bio-IT World | Absci and Almirall announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases; Stellaromics is developing next-generation spatial technology that promises to accelerate the development of fundamentally novel drug treatments, including for autoimmune diseases, cancer, and more; Aqtual intends to expand its platform that evaluates protein regulation, epigenetics, and transcriptomics; more.

    Nov 30, 2023

  • Greenphire, Florence Healthcare Team Up; Illumina Partnerships; Oxford Nanopore Develops New Data Technology

    Bio-IT World | Greenphire and Florence Healthcare announce a technology partnership; Illumina and Veracyte join together in a multi-year agreement; Oxford Nanopore Technologies collaborates with Fabric Genomics and Saphetor to develop data technology for research; more.

    Nov 29, 2023

  • NVIDIA, Genentech Launch Multi-Year Generative AI Research Collaboration

    Bio-IT World | Genentech and NVIDIA announced today a multi-year strategic AI research collaboration to accelerate drug discovery and development.

    Nov 21, 2023

  • 2023 European Best of Show Finalists Named

    Bio-IT World | Bio-IT World has named the Best of Show Awards finalists for competition at the 2023 Bio-IT World Conference & Expo Europe next week in London. New products from ACD/Labs, CCC, Medidata, ONTOFORCE, Sapio Sciences, and TetraScience will be on display at the event and the Bio-IT World community will vote to honor their favorite solutions.

    Nov 20, 2023

  • CRISPR Screens: A New Frontier in Drug Discovery, Research

    Bio-IT World | In 2012, Jennifer Doudna and Emmanuelle Charpentier at the University of California, Berkeley, and Feng Zhang at the Broad Institute of MIT and Harvard independently discovered that the CRISPR system could be used in human cells to target and edit DNA in a precise and programmable manner. This discovery revolutionized the field of genetic engineering and paved the way for the development of CRISPR screens.

    Nov 17, 2023

  • Owkin’s Generative AI Vision for Understanding Biology

    Bio-IT World | Generative AI in drug discovery is primarily a patient stratification play. Identifying which group of patients might best respond to a particular drug can still be foggy at best.

    Nov 15, 2023

  • Pharma’s Tech Partner Wish List

    Bio-IT World | What is pharma looking for in technology partners? That was the question posed to a panel representing Pfizer, Johnson & Johnson, GlaxoSmithKline, and AstraZeneca last month at the HLTH Conference. The answers revealed some of the trends these pharma companies expect to see in drug development and clinical trials, and the pain points they are actively addressing now.

    Nov 14, 2023

  • PacBio News: HiFi Consortium, Tertiary Partners, New RNA Kits

    Bio-IT World | Pacific Bioscience made several announcements this week at the American Society of Human Genetics Annual Meeting in Washington D.C. The sequencing company announced a new consortium focused on quantifying the value of HiFi sequencing, launched a family of RNA sequencing kits, and named two new tertiary analysis partners.

    Nov 9, 2023

  • Big Pharma, Moderna on An AI-Empowered Era of Drug Discovery

    Bio-IT World | In January, Heidi Rehm will take over the leadership of the Global Alliance for Genomics and Health, GA4GH, replacing out-going Chair Ewan Birney. Rehm sat down with Stan Gloss to talk about the mission of GA4GH and share areas of future focus for the latest episode of the Trends from the Trenches podcast.

    Nov 8, 2023

  • ‘Subway Map’ Approach To Finding Targeted Therapeutics For Lyme Disease

    Bio-IT World | Scientists in Boston are flipping the script on the current antibiotic development paradigm by painstakingly choosing a good metabolic target for combatting Lyme disease. The typical approach has been to test vast numbers of chemicals against the culprit bacteria rather than design a compound to specifically go after one of its essential biological activities.

    Nov 7, 2023

  • The Promising Future of AI in Synthetic Biology

    Bio-IT World | The synthetic biology landscape has evolved considerably to include new ways of accessing DNA for research and therapeutic development. An important advance is that DNA production is no longer limited to third-party suppliers.

    Nov 3, 2023

  • Dementia-Associated Protein Provides Clues About Preeclampsia

    Bio-IT World | Researchers at the University of Western Ontario and Brown University were surprised to discover an “almost identical mechanism” appearing in the blood and placenta of women with preeclampsia as has been previously found in the brains of older individuals with Alzheimer’s disease (AD), traumatic brain injury (TBI), and vascular dementia.

    Nov 1, 2023

  • New Chair, Heidi Rehm, on the Future Focus of the Global Alliance for Genomics and Health

    Bio-IT World | In January, Heidi Rehm will take over the leadership of the Global Alliance for Genomics and Health, GA4GH, replacing out-going Chair Ewan Birney. Rehm sat down with Stan Gloss to talk about the mission of GA4GH and share areas of future focus for the latest episode of the Trends from the Trenches podcast.

    Oct 31, 2023

  • Enkelejda Miho on Curiosity, Courage, and Advancing Research With Adisciplinary Approaches

    Bio-IT World | In the latest episode of The Chain podcast, host Ben Hackel, Professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Enkelejda “Ledi” Miho, Professor of Digital Life Sciences at the University of Applied Sciences Northwestern Switzerland FHNW, about the data challenges currently facing drug discovery, and how an adisciplinary approach would allow a more fruitful flow of ideas between indication silos, fueling discovery.

    Oct 27, 2023

  • NTT Corporation Joins Japan Precision Medicine Platform Project, FDA Gives Grant To Aspen Neuroscience, Cancer Research Horizons And Genialis Team Up

    Bio-IT World | NTT Corporation joins an agreement with BC Platforms AG, PRIME-R, and Bioxcellerator to develop the Japan Precision Medicine Platform (JPP), a secure information sharing platform for medical data designed to improve medical data analysis and medical research domestically across Japan; FDA grants Fast Track Designation for Aspen Neurosciencce Parkinson's disease treatment; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.

    Oct 26, 2023